Registry-listed formulations

forodesine hydrochloride · chembl:CHEMBL550755

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

5 source entries across 5 studies. This list may not include all unresolved or historical entries.

  • forodesine hydrochloride (BCX-1777)Registry intervention

    Linked study entry; product equivalence not established

    View study and source
  • forodesine hydrochloride (BCX-1777)Registry intervention

    Linked study entry; product equivalence not established

    View study and source
  • forodesine hydrochloride (BCX-1777)Registry intervention

    Linked study entry; product equivalence not established

    View study and source
  • Forodesine Hydrochloride Capsules (100 mg)Registry intervention

    Linked study entry; product equivalence not established

    View study and source
  • forodesine HClRegistry intervention

    Linked study entry; product equivalence not established

    View study and source

Success Metrics

Clinical Success Rate
100.0%

Based on 9 completed trials

Completion Rate
90%(9/10)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(10%)

Phase Distribution

Phase 1/2
3
30%
Phase 2
4
40%
Phase 1
3
30%

Phase Distribution

3

Early Stage

7

Mid Stage

0

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
3(30.0%)
Phase 1/2Combined phases
3(30.0%)
Phase 2Efficacy & side effects
4(40.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

90.0%

9 of 10 finished

Non-Completion Rate

10.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

10

all time

Status Distribution
Completed(9)
Terminated(1)

Detailed Status

Completed9
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
0
Success Rate
100.0%
Most Advanced
Phase 1/2

Trials by Phase

Phase 13 (30.0%)
Phase 1/23 (30.0%)
Phase 24 (40.0%)

Trials by Status

completed990%
terminated110%

Recent Activity

0 active trials
Showing 5 of 10
completedphase_1_2

Phase I/II Clinical Study of Forodesine in Japanese Recurrent/Refractory Peripheral T-cell Lymphoma Patients

NCT01776411
completedphase_1

Oral Forodesine Hydrochloride (BCX-1777) in Patients With Recurrent or Refractory T/NK-cell Malignancies

NCT00823355
completedphase_1

Forodesine (BCX-1777) in Treating Patients With Refractory Stage IIA, Stage IIB, Stage III, Stage IVA, or Stage IVB Cutaneous T-Cell Lymphoma

NCT00098332
completedphase_1_2

BCX-1777 in Treating Patients With Refractory Cutaneous T-Cell Lymphoma

NCT00061880
completedphase_1

BCX-1777 in Treating Patients With Refractory Cancer

NCT00073944
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT01776411Phase 1/2

Phase I/II Clinical Study of Forodesine in Japanese Recurrent/Refractory Peripheral T-cell Lymphoma Patients

Completed
NCT00823355Phase 1

Oral Forodesine Hydrochloride (BCX-1777) in Patients With Recurrent or Refractory T/NK-cell Malignancies

Completed
NCT00098332Phase 1

Forodesine (BCX-1777) in Treating Patients With Refractory Stage IIA, Stage IIB, Stage III, Stage IVA, or Stage IVB Cutaneous T-Cell Lymphoma

Completed
NCT00061880Phase 1/2

BCX-1777 in Treating Patients With Refractory Cutaneous T-Cell Lymphoma

Completed
NCT00073944Phase 1

BCX-1777 in Treating Patients With Refractory Cancer

Completed
NCT00289549Phase 2

Study of Forodesine Hydrochloride in Patients With Advanced, Fludarabine-refractory Chronic Lymphocytic Leukemia (CLL)

Completed
NCT00419081Phase 2

Study of Forodesine Hydrochloride in Patients With Relapsed/Refractory Precursor T-Lymphoblastic Leukemia/Lymphoma Who Have Failed Two or More Prior Treatment Regimens

Terminated
NCT00640523Phase 2

Phase II Study of Forodesine in Subjects With Chronic Lymphocytic Leukemia (CLL)

Completed
NCT00289562Phase 1/2

Forodesine Hydrochloride (BCX-1777) for B-Cell Acute Lymphoblastic Leukemia

Completed
NCT00095381Phase 2

Repeat-Dose of Forodesine Hydrochloride (BCX-1777) Infusion in Patients With Advanced T-Cell Leukemia

Completed

All 10 trials loaded

Drug Details

Intervention Type
Drug
Molecule Type
Small molecule
Total Trials
10

External References

ChEMBL
CHEMBL550755